What Is HHC and Why Is It Still Banned?

The hemp industry has spent the last several years riding a legal gray area created by the 2018 Farm Bill. Cannabinoids like delta-8 THC, THC-O, HHC, and countless other hemp-derived compounds flooded smoke shops, gas stations, and online marketplaces across the United States. Many were marketed as “legal highs” because the law specifically focused on delta-9 THC concentrations in hemp rather than the broader world of intoxicating cannabinoids.

Now, that loophole is rapidly closing.

As of May 4, 2026, hexahydrocannabinol, better known as HHC, is specifically listed by the Drug Enforcement Administration (DEA) as a Schedule I controlled substance under the Controlled Substances Act. While the DEA says HHC was already considered illegal under existing tetrahydrocannabinol rules, the new action formally names the compound and assigns it its own DEA drug code.

The move marks another major shift in the evolving battle over hemp-derived cannabinoids in America, and it highlights how quickly the post-Farm Bill cannabis landscape has changed. Let’s explore exactly what HHC is and why the DEA has officially listed HHC as a schedule I substance.

What Is HHC?

Hexahydrocannabinol is a cannabinoid chemically related to THC. It produces psychoactive effects similar to traditional cannabis, though many describe it as slightly milder and more clear-headed than delta-9 THC. HHC occurs naturally in cannabis in very small amounts, but the products sold commercially are typically created through chemical conversion processes. In most cases, manufacturers start with hemp-derived CBD and chemically alter it into HHC through hydrogenation and other laboratory methods.

That distinction is critically important. Under the Agriculture Improvement Act of 2018, better known as the Farm Bill, hemp and hemp-derived cannabinoids containing less than 0.3% delta-9 THC were removed from the federal definition of marijuana. The hemp industry interpreted this language broadly, leading to an explosion of intoxicating hemp-derived cannabinoids. However, the DEA has consistently argued that chemically converted cannabinoids are considered synthetic and therefore remain controlled substances under federal law. In the latest rule, the DEA states clearly that tetrahydrocannabinols produced through chemical conversion “do not qualify as ‘tetrahydrocannabinols in hemp’ under the AIA.”

Why Did HHC Become So Popular?

HHC gained traction because it occupied a confusing middle ground between cannabis and hemp laws. In states where marijuana remained illegal, HHC products were often sold openly in vape shops, convenience stores, and online stores without the same regulations imposed on licensed cannabis dispensaries. Consumers seeking psychoactive effects could legally purchase HHC gummies, vape cartridges, tinctures, and infused products in many parts of the country.

Part of the appeal was also practical. Some individuals reported that HHC produced relaxing and euphoric effects similar to THC. Others turned to cannabinoids like HHC and delta-8 THC because they wanted alternatives to prescription medications, alcohol, or stronger cannabis products.

Research on HHC remains limited, but anecdotal reports suggested possible benefits involving:

• Relaxation
• Stress reduction
• Mild pain relief
• Sleep support
• Appetite stimulation

Unfortunately, despite HHC’s potential benefits, the lack of regulation created serious problems.

The Hemp Industry’s Loophole Problem

The reality is that the hemp industry helped create the situation now unfolding. After the 2018 Farm Bill legalized hemp, many companies began aggressively manufacturing intoxicating cannabinoids from CBD isolates and marketing them as federally legal alternatives to marijuana. The market moved faster than regulators could respond.

Instead of focusing primarily on non-intoxicating cannabinoids like CBD, CBG, or industrial hemp applications, parts of the industry leaned heavily into producing increasingly potent psychoactive compounds. Delta-8 THC became the first major wave, followed by compounds like HHC, THC-O, THCP, and numerous others. Many products were marketed with flashy packaging, sold in unregulated environments, and sometimes lacked proper lab testing or age restrictions. Critics argued the industry was exploiting a technical loophole rather than honoring the original intent of hemp legalization.

That loophole largely centered around one key detail: the Farm Bill specifically referenced delta-9 THC concentration limits rather than all intoxicating cannabinoids. For years, that wording allowed companies to argue that hemp-derived intoxicants remained federally lawful if they originated from hemp and contained less than 0.3% delta-9 THC. Regulators increasingly pushed back against that interpretation, and now, federal agencies and state lawmakers are rewriting rules to close those gaps.

Why HHC Is Illegal

According to the DEA’s final rule, HHC already qualified as a Schedule I substance because it fits within the definition of tetrahydrocannabinols under federal law. The new rule does not technically “reschedule” HHC. Instead, it formally adds HHC as a separate listing in Schedule I and assigns it a unique DEA controlled substance code.

The agency states that because commercially produced HHC is created through chemical conversion, it is considered synthetic rather than naturally occurring hemp. The DEA also notes that the action follows international drug control decisions. In March 2025, the United Nations Commission on Narcotic Drugs voted to place HHC under Schedule II of the 1971 Convention on Psychotropic Substances. Following that decision, U.S. federal agencies moved to formally clarify HHC’s status domestically.

Under Schedule I classification, HHC now sits in the same federal category as recreational marijuana, heroin, and LSD. Schedule I substances are defined as having a high potential for abuse and no currently accepted medical use under federal law.

The Bigger Problem With Blanket Cannabinoid Bans

While some regulators view the crackdown as necessary consumer protection, others argue the response has become overly broad. One of the biggest concerns is that cannabinoids are being grouped together without sufficient scientific evaluation. HHC is not identical to delta-9 THC, and anecdotal research shows there may be meaningful therapeutic value from this compound that needs further investigation. However, federal policy continues to criminalize cannabinoids which limits research opportunities. Schedule I status creates major barriers for scientists attempting to study safety profiles, therapeutic potential, dosage, and long-term effects. This creates a paradox within cannabis policy. The government often argues there is insufficient evidence supporting cannabinoids, while the same scheduling framework makes robust research extremely difficult to conduct.

There are also many people who use hemp-derived cannabinoids for their therapeutic effects, such as sleep support, pain management, and anxiety relief, that may lose access entirely, even in states where marijuana remains illegal.

Blanket bans push us backwards, not forward.

What Happens Next for Hemp?

The HHC decision signals a broader turning point for the hemp industry. Federal and state regulators are increasingly drawing harder lines between non-intoxicating hemp products and psychoactive cannabinoids created through chemical conversion. Many experts expect additional restrictions on hemp-derived intoxicants in the coming years.

At the same time, the situation exposes how outdated and fragmented U.S. cannabis laws remain. The country now has a confusing patchwork where federally illegal marijuana is sold legally in many states, while hemp-derived cannabinoids bounce between legality and prohibition depending on chemistry, manufacturing methods, and regulatory interpretation.

For the hemp industry, the lesson is becoming impossible to ignore, exploiting legal gray areas may generate rapid profits in the short term, but it also invites aggressive regulatory backlash. And for consumers, the HHC crackdown serves as another reminder that cannabis and hemp policy in America is still far from settled.